|
| Status |
Public on Jan 15, 2016 |
| Title |
pdx control rep2 |
| Sample type |
RNA |
| |
|
| Source name |
patient derived xenograft
|
| Organism |
Homo sapiens |
| Characteristics |
treatment: control
tissue type: patient derived melanoma xenograft
|
| Treatment protocol |
Mice were treated with a control gapmer of GapmeR3 targeting LINC01212
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was extracted using the miRNeasy mini kit (Qiagen)
|
| Label |
Cy3
|
| Label protocol |
Total RNA (100ng) was labeled using the low input Quick Amp WT labeling kit (Agilent Technologies) according to the manufacturer’s instructions.
|
| |
|
| Hybridization protocol |
Labeled RNA was hybridized to a Agilent human gene expression microarray according to the manufacturer's instructions.
|
| Scan protocol |
Arrays were scanned using the Agilent G2565CA Microarray Scanner and Scan Control Software 8.5 according to the manufacturer's instructions.
|
| Data processing |
Probe intensities were extracted using Feature Extraction software (Agilent).
|
| |
|
| Submission date |
Jun 23, 2015 |
| Last update date |
Jan 15, 2016 |
| Contact name |
Pieter mestdagh |
| E-mail(s) |
[email protected]
|
| Organization name |
Center for Medical Genetics
|
| Street address |
De Pintelaan 185
|
| City |
Gent |
| ZIP/Postal code |
9000 |
| Country |
Belgium |
| |
|
| Platform ID |
GPL17077 |
| Series (2) |
| GSE70177 |
Targeting the lineage-specific long non-coding RNA LINC01212 as an effective anti-melanoma therapeutic strategy [2] |
| GSE70180 |
Targeting the lineage-specific long non-coding RNA LINC01212 as an effective anti-melanoma therapeutic strategy |
|
